Logo image of ALBLU.PA

BLUELINEA (ALBLU.PA) Stock Fundamental Analysis

EPA:ALBLU - Euronext Paris - Matif - FR0011041011 - Common Stock - Currency: EUR

0.93  0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALBLU. ALBLU was compared to 55 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ALBLU have multiple concerns. ALBLU does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALBLU has reported negative net income.
In the past year ALBLU had a positive cash flow from operations.
In the past 5 years ALBLU always reported negative net income.
ALBLU had a negative operating cash flow in each of the past 5 years.
ALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFALBLU.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

With a Return On Assets value of -16.32%, ALBLU is not doing good in the industry: 63.64% of the companies in the same industry are doing better.
ALBLU's Return On Equity of -115.32% is on the low side compared to the rest of the industry. ALBLU is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
ROA -16.32%
ROE -115.32%
ROIC N/A
ROA(3y)-22.53%
ROA(5y)-28.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBLU.PA Yearly ROA, ROE, ROICALBLU.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

ALBLU's Gross Margin of 103.22% is amongst the best of the industry. ALBLU outperforms 98.18% of its industry peers.
In the last couple of years the Gross Margin of ALBLU has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for ALBLU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 103.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.66%
GM growth 5Y1.04%
ALBLU.PA Yearly Profit, Operating, Gross MarginsALBLU.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

0

2. Health

2.1 Basic Checks

ALBLU does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALBLU has about the same amout of shares outstanding than it did 1 year ago.
ALBLU has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALBLU has a worse debt to assets ratio.
ALBLU.PA Yearly Shares OutstandingALBLU.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALBLU.PA Yearly Total Debt VS Total AssetsALBLU.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

ALBLU has an Altman-Z score of -2.68. This is a bad value and indicates that ALBLU is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.68, ALBLU is not doing good in the industry: 78.18% of the companies in the same industry are doing better.
ALBLU has a Debt/Equity ratio of 2.31. This is a high value indicating a heavy dependency on external financing.
ALBLU's Debt to Equity ratio of 2.31 is on the low side compared to the rest of the industry. ALBLU is outperformed by 83.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.31
Debt/FCF N/A
Altman-Z -2.68
ROIC/WACCN/A
WACC6.93%
ALBLU.PA Yearly LT Debt VS Equity VS FCFALBLU.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M 8M

2.3 Liquidity

ALBLU has a Current Ratio of 0.49. This is a bad value and indicates that ALBLU is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ALBLU (0.49) is worse than 85.45% of its industry peers.
A Quick Ratio of 0.44 indicates that ALBLU may have some problems paying its short term obligations.
The Quick ratio of ALBLU (0.44) is worse than 85.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.44
ALBLU.PA Yearly Current Assets VS Current LiabilitesALBLU.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

2

3. Growth

3.1 Past

ALBLU shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.35%, which is quite good.
The Revenue has decreased by -5.60% in the past year.
Measured over the past years, ALBLU shows a quite strong growth in Revenue. The Revenue has been growing by 9.78% on average per year.
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.56%
Revenue 1Y (TTM)-5.6%
Revenue growth 3Y12.92%
Revenue growth 5Y9.78%
Sales Q2Q%-6.48%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALBLU.PA Yearly Revenue VS EstimatesALBLU.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALBLU.PA Yearly EPS VS EstimatesALBLU.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALBLU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBLU.PA Price Earnings VS Forward Price EarningsALBLU.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

ALBLU's Enterprise Value to EBITDA is on the same level as the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 54
ALBLU.PA Per share dataALBLU.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALBLU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUELINEA

EPA:ALBLU (3/7/2025, 7:00:00 PM)

0.93

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners83.76%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap11.42M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.2
P/FCF N/A
P/OCF 37.27
P/B 7.82
P/tB N/A
EV/EBITDA 54
EPS(TTM)-0.14
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)0.02
OCFY2.68%
SpS0.77
BVpS0.12
TBVpS-0.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.32%
ROE -115.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 103.22%
FCFM N/A
ROA(3y)-22.53%
ROA(5y)-28.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.66%
GM growth 5Y1.04%
F-Score5
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 2.31
Debt/FCF N/A
Debt/EBITDA 13.16
Cap/Depr 144.22%
Cap/Sales 27.72%
Interest Coverage N/A
Cash Conversion 119.5%
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.44
Altman-Z -2.68
F-Score5
WACC6.93%
ROIC/WACCN/A
Cap/Depr(3y)140.81%
Cap/Depr(5y)112.84%
Cap/Sales(3y)19.23%
Cap/Sales(5y)15.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.6%
Revenue growth 3Y12.92%
Revenue growth 5Y9.78%
Sales Q2Q%-6.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-232.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y921.33%
OCF growth 3YN/A
OCF growth 5YN/A